The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
MyChesCo on MSN
AstraZeneca and Amgen Secure FDA Approval for TEZSPIRE to Treat Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an ...
Nasal polyps are soft growths that can develop in your nose as a result of long-term swelling — from colds, allergies, and other conditions — in your nasal passages. They are more common in people who ...
Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...
FDA moves to pull nasal decongestant in some cold medicines from shelves amid effectiveness concerns
WASHINGTON -- The US Food and Drug Administration announced a proposal to remove oral phenylephrine - a common ingredient in many popular over-the-counter decongestants - from the market, citing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback